Fallopian Tube Neoplasms
Information
- Disease name
- Fallopian Tube Neoplasms
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05116189 | Active, not recruiting | Phase 3 | Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) | December 13, 2021 | August 31, 2027 |
| NCT05257408 | Active, not recruiting | Phase 3 | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer | June 29, 2022 | June 2025 |
| NCT04498117 | Active, not recruiting | Phase 3 | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | August 25, 2020 | August 26, 2027 |
| NCT01932125 | Active, not recruiting | Phase 4 | An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | December 5, 2018 | June 21, 2025 |
| NCT00112086 | Completed | Phase 2 | OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206 | January 2003 | February 2007 |
| NCT00189345 | Completed | Phase 2 | Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients | May 2004 | October 2005 |
| NCT00191607 | Completed | Phase 3 | A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. | July 2002 | November 2005 |
| NCT00191646 | Completed | Phase 3 | An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy | October 2002 | August 2009 |
| NCT00391118 | Completed | Phase 2 | Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") | November 2006 | July 2012 |
| NCT00035100 | Completed | Phase 2 | EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer | September 2001 | |
| NCT00415207 | Completed | Pharmacogenomics of Paclitaxel in Ovarian Cancer | December 2006 | December 2010 | |
| NCT00443196 | Completed | Phase 2/Phase 3 | Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas | March 2006 | September 2010 |
| NCT00698451 | Completed | Phase 2 | A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers | August 2008 | October 2010 |
| NCT00415181 | Completed | Pharmacogenomics of Paclitaxel in Ovarian Cancer | September 2006 | March 2013 | |
| NCT00063401 | Completed | Phase 2 | Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | September 2003 | June 2006 |
| NCT00074867 | Completed | Phase 2 | Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer | October 2003 | September 2004 |
| NCT00103545 | Completed | Phase 1/Phase 2 | Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response | July 2003 | August 2004 |
| NCT01313078 | Completed | Phase 2 | Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer | January 2010 | September 2011 |
| NCT01462890 | Completed | Phase 3 | Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer | November 2011 | December 2021 |
| NCT01478685 | Completed | Phase 1 | A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors | November 29, 2011 | November 17, 2015 |
| NCT01846611 | Completed | Phase 3 | A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | October 16, 2013 | November 16, 2018 |
| NCT02444195 | Completed | N/A | Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients | April 2015 | May 1, 2016 |
| NCT02658214 | Completed | Phase 1 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | April 28, 2016 | November 14, 2019 |
| NCT02786524 | Completed | N/A | Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy | February 15, 2016 | October 31, 2017 |
| NCT02903771 | Completed | Phase 1 | Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. | November 2016 | March 24, 2020 |
| NCT03593681 | Completed | Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy | August 27, 2018 | February 14, 2020 | |
| NCT04807166 | Not yet recruiting | Phase 2 | Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer | June 1, 2021 | December 1, 2024 |
| NCT04794322 | Recruiting | Developing a Test for the Detection of Ovarian Cancer | April 13, 2020 | March 2025 | |
| NCT03976999 | Recruiting | N/A | Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers | July 5, 2017 | January 2027 |
| NCT04111978 | Recruiting | Phase 3 | MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) | November 5, 2020 | October 1, 2030 |
| NCT04196257 | Recruiting | Phase 1 | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | August 19, 2022 | October 2024 |
| NCT05960630 | Recruiting | N/A | MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer | October 2, 2023 | December 31, 2024 |
| NCT05194072 | Recruiting | Phase 1 | A Study of SGN-B7H4V in Advanced Solid Tumors | January 12, 2022 | January 31, 2027 |
| NCT05605535 | Recruiting | Phase 2 | Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | February 7, 2023 | May 15, 2026 |
| NCT06223763 | Recruiting | SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery | January 1, 2024 | June 1, 2024 | |
| NCT05617755 | Recruiting | Phase 1 | AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer | November 29, 2022 | February 2027 |
| NCT01681368 | Terminated | Phase 2 | Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer | August 15, 2012 | April 30, 2014 |
| NCT01279291 | Terminated | Phase 1 | Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer | January 2011 | November 2012 |
| NCT00407407 | Terminated | Phase 1 | ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma | November 1, 2006 | February 1, 2008 |
| NCT00445549 | Terminated | Phase 2 | Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | January 2007 | October 2009 |
| NCT02478476 | Unknown status | DNA Single Nucleotide Polymorphisms as Predictors of Toxicity | July 2015 | December 2017 | |
| NCT03000192 | Unknown status | HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life | August 2016 | September 2021 | |
| NCT03648489 | Unknown status | Phase 2 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | September 21, 2018 | December 2022 |
| NCT04556071 | Unknown status | Phase 2 | Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer | November 6, 2020 | October 1, 2022 |
| NCT01766622 | Withdrawn | Phase 2 | 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant | November 30, 2012 | July 24, 2013 |
| NCT01228942 | Withdrawn | N/A | A Prospective Trial of COXEN Chemotherapy Prediction | October 2010 | June 2013 |
| NCT01131039 | Withdrawn | Phase 2 | Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer | January 2011 | September 2011 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D005185